University Hospitals UH to take part in ACTIV-2 covid-19 trial

The Cleveland-based hospital system is currently looking for people who have tested positive for the Coronavirus to take part in the trial.

CLEVELAND — Editor’s note: the video in the player above is from a story published on October 22, 2020. 

University Hospitals (UH) continues to do it’s part in the search for answers surrounding the Coronavirus. 

The hospital system announced on Thursday that it will take part in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. 

In a press release, a representative for UH said that the clinical trial will take a deeper look at adults who have previously tested positive for COVID-19, but did not require hospitalization. UH is one of 25 hospitals nationwide to take part in the new trial. 

RELATED: University Hospitals joins Western Reserve Hospital as minority partner

“This study aims to identify a treatment that can prevent people with COVID-19 from developing advanced disease that requires hospitalization,” said Grace McComsey, MD, Vice President of Research and Associate Chief Scientific Officer at UH. “UH is at the forefront of testing experimental treatments for COVID-19, including remdesivir, stem cell therapy and convalescent plasma. Patients suffering from complications of COVID-19 have hope at UH thanks to these options.”

UH has also partnered with the Case Western Reserve University (CWRU) School of Medicine in the study that is sponsored by the National Institue of Allergy and Infectious Diseases (NIADID) and the National Institute of Health (NIH). 

“The need for effective treatments is critical in the fight against COVID-19. While people with the disease may start off with just a few minor symptoms, they can rapidly become very ill,” said Dr. Jeffrey Jacobson, an attending physician at UH Medical Center. “People living in Northeast Ohio who have recently been diagnosed with COVID-19 and are not hospitalized have the opportunity to make a huge contribution by participating in this study.”

RELATED: University Hospitals, Case Western Reserve University announce study of AstraZeneca’s COVID-19 vaccine candidate

For more information on the ACTIV-2 trial, click here. 

Eligible candidates must have tested positive for SARS-CoV-2 without hospitalization and experienced symptoms of the Coronavirus within 10 days of the trials start. 

UH is also making sure that the blind study has a participant pool that includes people at high-risk for severe illness due to COVID-19, including conditions like lung, kidney, or liver disease, obsesity, diabetes, or asthma 

For information about enrolling in the trial at University Hospitals, you can email [email protected] or call 1-838-78-TRIAL.


Source Article